Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 17/20 | 0.58 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.42 |
| ▸ | ILK | Q13418 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028033 | 1.00 | ALOX5 (0.58) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL6027939 | 1.00 | ALOX5 (0.58) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL8600009 | 0.89 | ALOX5 (0.62) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL20819450 | 0.84 | ALOX5 (0.44) | ALOX5AKT1NR1I2 | |
| SCHEMBL20819449 | 0.84 | ALOX5 (0.44) | ALOX5AKT1NR1I2 | |
| SCHEMBL8746297 | 0.82 | ALOX5 (0.56) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL8747773 | 0.82 | ALOX5 (0.56) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL2484255 | 0.81 | ALOX5 (0.48) | ALOX5AKT1PDPK1PHLPP1ILK | |
| SCHEMBL4643458 | 0.81 | ALOX5 (0.66) | ALOX5NR1I2 | |
| Bromide SCHEMBL8599204 | 0.81 | ALOX5 (0.56) | ALOX5AKT1PDPK1PHLPP1ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124687-A1 | Process for synthesizing d-tocotrienols | COULADOUROS ELIAS A (GR) | 2005-06-09 | — | — | US | disclosed |
| WO-2005035490-A2 | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS | YASOO HEALTH, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124687-A1 | Process for synthesizing d-tocotrienols | UGT8, DDOST, GGPS1 | ALOX5 219/4885AKT1 3679/4885PDPK1 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.